Abstract
The paper reports the results of ribomunil trial in chronic bronchitis (CB) patients who suffered from frequent exacerbations. The drug was found to act primarily on a phagocytic component of the immunity and local immunity of the respiratory mucosa. Because of its vaccine-like effect, ribomunil administration is most beneficial in CB remission. Ribomunil treatment results in reduction of the number and duration of CB exacerbations, of the scope of antibacterial therapy.
Publication types
-
Clinical Trial
-
Comparative Study
-
English Abstract
MeSH terms
-
Adjuvants, Immunologic / adverse effects
-
Adjuvants, Immunologic / therapeutic use*
-
Adolescent
-
Adult
-
Antibody Formation / drug effects
-
Antigens, Bacterial / adverse effects
-
Antigens, Bacterial / therapeutic use*
-
Bronchitis / drug therapy*
-
Bronchitis / immunology
-
Chronic Disease
-
Humans
-
Immunity, Cellular / drug effects
-
Middle Aged
-
Placebos
Substances
-
Adjuvants, Immunologic
-
Antigens, Bacterial
-
Placebos
-
Ribomunyl